Bonk (NASDAQ:BNKK) Stock Price Down 1.6% – Should You Sell?

Bonk, Inc. (NASDAQ:BNKK) shares traded down 1.6% on Thursday. The company traded as low as $1.14 and last traded at $1.20. 87,605 shares changed hands during trading, a decline of 85% from the average daily volume of 587,896 shares. The stock had previously closed at $1.22.

Wall Street Analysts Forecast Growth

BNKK has been the subject of several analyst reports. Wall Street Zen upgraded Bonk from a “sell” rating to a “hold” rating in a research report on Saturday, July 4th. Weiss Ratings restated a “sell (e+)” rating on shares of Bonk in a research report on Friday, July 24th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Bonk Stock Up 0.8%

The business’s 50 day moving average is $1.34 and its two-hundred day moving average is $1.67. The firm has a market capitalization of $9.68 million, a P/E ratio of -0.32 and a beta of 1.91.

Bonk (NASDAQ:BNKK) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.76) earnings per share for the quarter. The company had revenue of $1.16 million during the quarter. Bonk had a negative return on equity of 137.47% and a negative net margin of 952.21%.

Institutional Trading of Bonk

A hedge fund recently bought a new stake in Bonk stock. BlackRock Inc. acquired a new stake in Bonk, Inc. (NASDAQ:BNKK) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 33,188 shares of the company’s stock, valued at approximately $50,000. BlackRock Inc. owned approximately 0.41% of Bonk at the end of the most recent reporting period. 12.55% of the stock is currently owned by institutional investors.

About Bonk

Safety Shot, Inc, a wellness and functional beverage company, engages in the research and development of over-the-counter products and intellectual property. Its products pipeline includes Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women’s sexual wellness; NoStingz, a jellyfish sting prevention sunscreen; and JW-110 for the treatment of atopic dermatitis/eczema. The company primarily sell its products through third-party physical retail stores and partners. The company was formerly known as Jupiter Wellness, Inc and changed its name to Safety Shot, Inc in September 2023.